Angiogenic factors in human proliferative sickle cell retinopathy

British Journal of Ophthalmology

Volumn 83, Issue 7, 1999, Pages 838-846

  Cao, Jingtai ^a   Mathews, Michaela Kunz ^a   McLeod, D Scott ^a   Merges, Carol ^a   Hjelmeland, Leonard M ^b   Lutty, Gerard A ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; COLLAGEN TYPE 2; COLLAGEN TYPE 4; HEPARAN SULFATE; HUMAN SERUM ALBUMIN; PROTEOGLYCAN; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; RETINA BLOOD VESSEL; SICKLE CELL ANEMIA; VASCULAR ENDOTHELIUM;

EID: 0032800917     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.83.7.838     Document Type: Article

References (37)

1. Sickle Cell Disease Guideline Panel. Sickle cell disease: screening, diagnosis, management, and counseling in newborns and infants. Clinical practice guideline no 6. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services, 1993:7-10.
2. Talbot JF, Bird AC, Maude GH, et al. Sickle cell retinopathy in Jamaican children: further observations from a cohort study. Br J Ophthalmol 1988;72:727-32.
3. McLeod D, Goldberg M, Lutty G. Dual perspective analysis of vascular formations in sickle cell retinopathy. Arch Ophthalmol 1993;111:1234-45.
4. Lutty G, Goldberg M. Ophthalmologic complications. In: Embury SD, Hebbel RP, Mohandas N, Steinberg MH, eds. Sickle cell disease: basic principles and clinical practice. New York: Raven Press, 1994:703-24.
5. Lutty G, Merges C, Crone S, et al. Immunohistochemical insights into sickle cell retinopathy, Curr Eye Res 1994;13:125-38.
6. Hanneken A, de Juan E, Lutty G, et al. Altered distribution of basic fibroblast growth factor in diabetic retinopathy. Arch Ophthalmol 1991;109:1005-11.
7. Boulton M, Foreman D, William G, et al. VEGF localisation in diabetic retinopathy. Br J Ophthalmol 1998;82:561-8.
8. Amin RH, Frank RN, Kennedy A, et al. Vascular endothelial growth factor is present in ghal cells of the retina and optic nerve of human subjects with nonprol iterative diabetic retinopathy. Invest Ophthalmol Vis Sci 1997;38:36-47.
9. Kunz Mathews M, Merges C, McLeod DS, et al. . Vascular endothelial growth factor (VEGF) and vascular permeability changes in human diabetic retinopathy. Invest Ophthalmol Vis Sci 1997;38:2729-41.
10. Lutty GA, McLeod DS, Merges C, et al. Localization of VEGF in human retina and choroid. Arch Ophthalmol 1996;114:971-7.
11. Dvorak HF, Sioussat TM, Brown LF, et al. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med 1991;174:1275-8.
12. Aiello LP, Northrup JM, Keyt BA, et al. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995;113:1538-14.
13. Shima DT, Deutsch U, D'Amore P. Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability. FEBS Lett 1995;370:203-8.
14. Goldberg MR Retinal neovascularization in sickle cell retinopathy. Trans Am Acad Ophthalmol Otolaryngol 1977;83:409-31.
15. Lutty GA, Merges G, Threlkeld AB, et al. Heterogeneity in localization of isoforms of TGF-β in human retina, vitreous, and choroid. Invest Ophthalmol Vis Sci 1993;34:477-87.
16. Healy AM, Herman IM. Density-dependent accumulation of basic fibroblast growth factor in the subendothelial matrix. Eur J Cell Biol 1992;59:56-67.
17. Ljubimov AW, Burgeson RE, Butkowski RJ, et al. Basement membrane abnormalities in human eyes with diabetic retinopathy. J Histochem Cytochem 1996;44:1469-79.
18. McLeod D, Lefer D, Merges C, et al. Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic retina and choroid. Am J Pathol 1995;147:642-53.
19. Page C, Rose M, Yacoub M, et al. Antigenic heterogeneity of vascular endothelium. Am J Pathol 1992;141:673-83.
20. Lutty GA, Merges C, McLeod DS. 5′ Nucleotidase and adenosine during retinal vasculogenesis and oxygeninduced retinopathy. Invest Ophthalmol Vis Sci 1999; (submitted).
21. Taomoto M, McLeod DS, Merges C, et al. . Localization of adenosine A2a receptor in retinal development and oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 1999;(submitted).
22. McLeod DS, Merges C, Fukushima A, et al. Histopathological features of neovascularization in sickle cell retinopathy. Am J Ophthalmol 1997;124:473-87.
23. Vinores SA, Campochiaro PA, Lee A, et al. Localization of blood-retinal barrier breakdown in human pathologic specimens by immunohistochemical staining for albumin. Lab Invest 1990;62:742-50.
24. Pe'er J, Shweiki D, Itin A, et al. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 1994;72:638-45.
25. Shima DT, Gougos A, Miller JW, et al. Cloning and mRNA expression of VEGF in ischemic retinas of Macacca fasicularis. Invest Ophthalmol Vis Sci 1996;37:1334-40.
26. Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994;145:575-84.
27. Simorre-Pinatel V, Guerrin M, Chollet P, et al. Vasculotropin-VEGF stimulates retinal capillary endothelial cells through an autocrine pathway. Invest Ophthalmol Vis Sci 1994;35:3393-400.
28. Goldberg MR Sickle cell retinopathy. Clinical ophthalmology. Hagerstown, MD: Harper and Row, 1976:1-44.
29. Stavri GT, Ying H, Zachry I, et al. Hypoxia and plateletderived growth factor-BB synergistically upregulate the expression of vascular endothelial cell growth factor in vascular smooth muscle cells. FEBS Lett 1995;358:311-15.
30. Shima DT, Adamis AP, Ferrara N, et al. Hypoxic induction of vascular endothelial growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med 1995;1:182-93.
31. Bost LM, Aotaki-Keen AE, Hjelmeland LM. Coexpression of FGF-5 and bFGF by retinal pigment epithelium in vitro. Exp Eye Res 1992;55:727-34.
32. Gaudry M, Bregerie O, Andrieu V, et al. Intracellular pool of vascular endothelial growth factor in human neutrophils, Blood 1997;90:4153-61.
33. Taichman NS, Young S, Cruchley AT, et al, Human neutrophils secrete vascular endothelial growth factor. J Leuk Biol 1997;62:397-100.
34. Kunz Mathews M, Cao J, Merges C, et al. Adhesion molecules, neutrophils and imbalance in the fibrinolytic system in sickle cell retinopathy. Invest Ophthalmol Vis Sci 1997;38(suppl):S1117.
35. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxiainitiated angiogenesis. Nature 1992;359:843-5.
36. Chen Y-S, Hackett SF, Schoenfeld C-L, et al. Localisation of vascular endothelial growth factor and its receptors to cells of vascular and avascular epiretinal membranes. Br J Ophthamol 1997;81:919-26.
37. Nauck M, Roth M, Eickelberg O, et al. Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids. Am J Respir Cell Mol Biol 1997;16:398-406.